Browse the corpus

Diabetic ketoacidosis (DKA) represents a serious, potentially life-threatening complication of diabetes characterized by hyperglycemia, acidosis, and ketonemia. Although most often associated with type 1 diabetes, it can also occur in patients with type 2 diabetes. This course reviews precipitating factors that commonly include new-onset diabetes, infections, nonadherence to therapy, and acute medical stressors. Certain medications, including corticosteroids, thiazides, antipsychotics, SGLT-2 inhibitors, and GLP-1 agonists, which further increase risk, with some agents predisposing patients to euglycemic DKA, are also discussed. Participants will also gain an understanding of immune checkpoint inhibitors, which have been linked to new-onset diabetes presenting with DKA. Recognition of diverse presentations, including atypical or drug-induced forms, remains essential for timely management. This course explores DKA pathophysiology, diagnostic criteria, precipitating factors, and treatment strategies, as well as typical and atypical DKA presentations, assessment for underlying causes, and implementation of evidence-based interventions such as fluid resuscitation, insulin therapy, electrolyte management, and infection control. This activity for healthcare professionals is designed to enhance the learner's competence in identifying DKA, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition. Objectives: Identify presentations of diabetic ketoacidosis, including euglycemic DKA associated with medications and immune checkpoint inhibitors. Interpret laboratory findings of diabetic ketoacidosis, including acid-base balance, ketone measurements, and electrolyte status, to guide clinical decisions. Implement evidence-based strategies for fluid resuscitation, insulin administration, and electrolyte replacement in patients with diabetic ketoacidosis. Apply care coordination strategies among an interprofessional team to optimize outcomes for patients affected by diabetic ketoacidosis. Access free multiple choice questions on this topic.

Diabetic ketoacidosis (DKA) represents a critical metabolic emergency marked by hyperglycemia, acidosis, and ketonemia. Although most frequently associated with type 1 diabetes, the condition can also affect individuals with type 2 diabetes under certain circumstances. The severity of DKA stems from its rapid onset and potential to cause significant morbidity and mortality if unrecognized or untreated. The development of DKA commonly results from new-onset diabetes, underlying infections, or poor adherence to therapy. Additional stressors such as acute illness, trauma, or medication effects may also precipitate the condition. Early identification and prompt management remain essential, as timely intervention greatly improves patient outcomes.

Diabetic Ketoacidosis Etiologies DKA develops more frequently in patients with type 1 diabetes, although patients with type 2 diabetes also face a significant risk. Common precipitating factors include new-onset diabetes, acute medical conditions, and nonadherence to therapy. Catabolic stress from acute illnesses or injuries, eg, infections, urinary tract infections, pneumonia, trauma, pulmonary embolism, and myocardial infarction, often contributes to the onset of DKA. Several drugs that interfere with carbohydrate metabolism, including corticosteroids, sympathomimetic agents, thiazides, and pentamidine, can also trigger DKA.[1] Conventional and atypical antipsychotics may cause hyperglycemia and, in rare cases, lead to DKA.[2] Euglycemic diabetic ketoacidosis While hyperglycemia typically serves as the hallmark of DKA, a subset of patients may develop euglycemic DKA, characterized by high anion gap metabolic acidosis with positive serum and urine ketones, despite glucose levels below 250 mg/dL. This condition often arises in patients receiving insulin who are underdosed or acutely decompensated.[3] Sodium-glucose cotransporter 2 (SGLT2)  inhibitors and GLP-1 agonists represent important contributors to euglycemic DKA.[4] SGLT-2 inhibitors lower insulin requirements but can promote lipolysis, ketogenesis, and glucagon secretion while reducing renal ketone clearance, thereby increasing plasma ketone levels.[5] GLP-1 agonists delay gastric emptying, suppress glucagon, and increase insulin secretion, which may induce hypoglycemia and a starvation state that accelerates lipolysis and ketosis. Their adverse effects, including nausea and vomiting, can further worsen ketosis, ultimately leading to DKA.[6][7] Euglycemic DKA may also occur in pregnancy.[8] Immune checkpoint inhibitor diabetes mellitus The expanding use of immune checkpoint inhibitors (ICIs) in oncology has improved cancer outcomes but introduced new immune-related adverse events. Endocrinopathies represent the most frequent of these, with a subset presenting as immune checkpoint inhibitor diabetes mellitus (ICI-DM). Patients with ICI-DM typically have no prior history of diabetes and often present with DKA. Substance abuse-induced diabetic ketoacidosis

The expanding use of immune checkpoint inhibitors (ICIs) in oncology has improved cancer outcomes but introduced new immune-related adverse events. Endocrinopathies represent the most frequent of these, with a subset presenting as immune checkpoint inhibitor diabetes mellitus (ICI-DM). Patients with ICI-DM typically have no prior history of diabetes and often present with DKA. Substance abuse-induced diabetic ketoacidosis Substance use also increases the risk of DKA. Cocaine abuse has been identified as an independent risk factor for recurrent DKA, while cannabis use increases the likelihood of DKA in patients with diabetes.[9] Chronic cannabis users may experience cannabinoid hyperemesis, which can precipitate recurrent DKA episodes.[10]

DKA incidence ranges from 0 to 56 per 1000 person-years, as shown in different studies from different geographic areas. DKA has a higher prevalence rate among women and individuals of ethnicities other than White. The incidence is higher among patients using injectable insulin compared to those using subcutaneous insulin infusion pumps.[11] Rates of DKA among children vary widely from country to country. The lowest incidence was found in Nigeria (2.9 cases per 100,000). The highest incidence rates were found in Sweden and Finland, at 41.0 and 37.4 per 100,000, respectively.[12] In the United States, nursing home residents accounted for 0.7% of DKA cases in a study. Increased mortality was associated with nursing home residence among patients with DKA.[13] Mortality rate greater than 5% has been reported in older adult patients and patients with concomitant life-threatening illnesses. Death in these conditions is rarely because of the metabolic complications of hyperglycemia or ketoacidosis alone. The prognosis substantially worsens at the extremes of age in the presence of coma, hypotension, and severe comorbidities.[2] In urban Black patients, poor adherence to taking insulin was the leading precipitating cause of DKA. Substance abuse is a significant contributing factor to non-adherence to therapies. Enhanced patient education and improved access to medical care help reduce the development of these hyperglycemic emergencies.[14] DKA is a life-threatening but preventable complication of diabetes. The Centers for Disease Control (CDC) United States Diabetes Surveillance System (USDSS) indicated an increase in hospitalization rates for DKA from 2009 to 2014, most notably in persons younger than 45 years.[15] However, overall mortality due to hyperglycemic crisis among adults with diabetes has declined in the United States. The scope for further improvement remains, especially to further reduce death rates among Black men and to prevent deaths occurring at home.[16]

DKA is a life-threatening but preventable complication of diabetes. The Centers for Disease Control (CDC) United States Diabetes Surveillance System (USDSS) indicated an increase in hospitalization rates for DKA from 2009 to 2014, most notably in persons younger than 45 years.[15] However, overall mortality due to hyperglycemic crisis among adults with diabetes has declined in the United States. The scope for further improvement remains, especially to further reduce death rates among Black men and to prevent deaths occurring at home.[16] The geriatric population is at particular risk for developing hyperglycemic crises with the development of diabetes. Some of the causes are increased insulin resistance and a decrease in the thirst mechanism. Older adults are particularly vulnerable to hyperglycemia and dehydration, the critical components of hyperglycemic emergencies. With increased diabetes surveillance and aggressive early treatment of hyperglycemia and its complications, morbidity, and mortality from acute diabetic crises in the geriatric population can be significantly reduced.[17]

Diabetes mellitus is characterized by insulin deficiency and increased plasma glucagon levels, which can be normalized by insulin replacement.[18][19][18] Typically, when serum glucose concentration rises, it enters pancreatic beta cells, leading to insulin production. Insulin decreases hepatic glucose production by inhibiting glycogenolysis and gluconeogenesis. Glucose uptake by skeletal muscle and adipose tissue is increased by insulin. Both of these mechanisms result in the reduction of blood sugar. In DKA, insulin deficiency and increased counter-regulatory hormones can lead to increased gluconeogenesis, accelerated glycogenolysis, and impaired glucose utilization. This will ultimately cause worsening hyperglycemia.[20] Insulin deficiency and increased counterregulatory hormones also lead to the release of free fatty acids into circulation from adipose tissue (lipolysis), which undergo hepatic fatty acid oxidation to ketone bodies (beta-hydroxybutyrate and acetoacetate), resulting in ketonemia and metabolic acidosis.[2] Glucagon is not crucial for the development of ketoacidosis in diabetes mellitus, as has previously been mentioned; however, glucagon may accelerate the onset of ketonemia and hyperglycemia in situations of insulin deficiency.[21] Patients treated with SGLT2 are at increased risk of developing euglycemic DKA. Diuresis induced by hyperglycemia, dehydration, hyperosmolarity, and electrolyte imbalance results in a decrease in glomerular filtration. Due to worsening renal function, hyperglycemia and hyperosmolality worsen. Potassium utilization by skeletal muscle is also impaired by hyperosmolality and impaired insulin function. This results in intracellular potassium depletion. Osmotic diuresis also leads to the loss of potassium, resulting in a low total body potassium level. The potassium level in patients with DKA varies, and a patient's normal plasma potassium level might indicate low total body potassium.[9] Hyperosmolarity appears to be the main factor responsible for the lowering of consciousness in patients with DKA.[22]

Diuresis induced by hyperglycemia, dehydration, hyperosmolarity, and electrolyte imbalance results in a decrease in glomerular filtration. Due to worsening renal function, hyperglycemia and hyperosmolality worsen. Potassium utilization by skeletal muscle is also impaired by hyperosmolality and impaired insulin function. This results in intracellular potassium depletion. Osmotic diuresis also leads to the loss of potassium, resulting in a low total body potassium level. The potassium level in patients with DKA varies, and a patient's normal plasma potassium level might indicate low total body potassium.[9] Hyperosmolarity appears to be the main factor responsible for the lowering of consciousness in patients with DKA.[22] New data suggest that hyperglycemia leads to a severe inflammatory state and an increase in proinflammatory cytokines (tumor necrosis factor-alpha and interleukin-beta, interleukin-6, and interleukin-8), C-reactive protein, lipid peroxidation, and reactive oxygen species, as well as cardiovascular risk factors, plasminogen activator inhibitor-1, and free fatty acids in the absence of apparent infection or cardiovascular pathology. After insulin therapy and intravenous (IV) fluid hydration, proinflammatory cytokine levels return to normal within 24 hours.[2]

Clinical History The patient with DKA may present with a myriad of clinical manifestations. Patients may have symptoms of hyperglycemia, eg, polyphagia, polyuria, or polydipsia. As patients become more volume-depleted, they may experience decreased urine output, a dry mouth, or decreased sweating, all of which are indicative of dehydration. Additionally, patients may report various other symptoms, including anorexia, nausea, vomiting, abdominal pain, and weight loss. If a superimposed infection triggers the episode of DKA, the patient may exhibit other infectious symptoms, including fever, cough, or urinary symptoms. In patients who may be developing cerebral edema, headache, or confusion may be present. In addition to other clinical history, a medication and social history should also be elicited to screen for drug and substance-induced DKA, including the prescribed medications and substance use (drugs and alcohol).[23] Physical Examination On physical examination, vital signs frequently reveal tachycardia and tachypnea. In cases with an infectious etiology for DKA, the patient may exhibit febrile or hypothermic symptoms. Blood pressure may also vary, though hypotension is possible and indicative of a more severe disease process. Patients are often ill-appearing. Kussmaul breathing, characterized by labored, deep, and tachypneic respirations, may occur. Clinicians may sometimes appreciate a fruity scent to the patient's breath, indicative of the presence of acetone. Patients may have signs of dehydration, including poor capillary refill, skin turgor, and dry mucous membranes. Abdominal tenderness is possible. In the most severe cases, altered mental status, general drowsiness, and focal neurologic deficits can be appreciated and are signs of cerebral edema. If found, this needs to be treated immediately.[24]

Adult Diabetic Ketoacidosis Criteria Commonly accepted criteria for DKA include blood glucose levels greater than 250 mg/dL, an arterial pH of less than 7.3, a serum bicarbonate level of less than 15 mEq/L, and the presence of ketonemia or ketonuria. The reference range for an anion gap is typically 12 mEq/L; an anion gap greater than 14 to 15 mEq/L indicates the presence of an increased anion gap metabolic acidosis.[25] The arterial pH may be normal or even raised if other types of metabolic or respiratory alkalosis coexist, eg, in individuals with vomiting or diuretic use.[26] Blood glucose may be normal or minimally elevated in patients with DKA (<300 mg/dL), where the underlying risk of hypoglycemia preexists, eg, in patients with alcohol use disorder or patients receiving insulin or SGLT2 inhibitors.[27] Furthermore, the majority of patients with DKA who present to the hospital are found to have leukocytosis. The laboratory serum sodium finding is often falsely low in DKA cases and can be corrected by adding 1.6 mEq to the measured serum sodium for each 100 mg/dL of glucose above 100 mg/dL. Serum potassium is usually elevated because of a shift of potassium from the intracellular to the extracellular space caused by acidosis and insulin deficiency. However, total body potassium may be depleted or become depleted quickly with insulin administration. Magnesium is often low and requires repletion as well. The serum phosphate level in DKA may be elevated despite total-body phosphate depletion.[28] Diagnostic Evaluation of Precipitating Conditions Other laboratory studies, eg, cultures of urine, sputum, and blood, as well as serum lipase, may need to be performed depending on the clinical presentation to help identify underlying precipitating conditions. Pneumonia and urinary tract infections are the most common infectious catalysts of DKA. Additionally, glycated hemoglobin (A1C) measurements may provide information regarding a patient's glucose trends over time.

Other laboratory studies, eg, cultures of urine, sputum, and blood, as well as serum lipase, may need to be performed depending on the clinical presentation to help identify underlying precipitating conditions. Pneumonia and urinary tract infections are the most common infectious catalysts of DKA. Additionally, glycated hemoglobin (A1C) measurements may provide information regarding a patient's glucose trends over time. In acute DKA, the ketone body ratio (3-beta-hydroxybutyrate: acetoacetate) increases from a reference range of 1:1 to as high as 10:1. In response to insulin therapy, 3-beta-hydroxybutyrate (3-HB) levels typically decrease before acetoacetate levels. The frequently employed nitroprusside test only detects acetoacetate in blood and urine, not in other bodily fluids. This test provides only a semiquantitative assessment of ketone levels and is associated with false-positive results. Recently, inexpensive quantitative tests for 3-HB levels have become available for widespread use, offering options for monitoring and treating diabetes and other conditions characterized by abnormal ketone body metabolism.[29] Pancreatic enzyme serum levels may be elevated in DKA due to a disorder in carbohydrate metabolism.[30] Therefore, in DKA cases, patients presenting with abdominal pain and elevated pancreatic enzymes should not be immediately diagnosed with acute pancreatitis.[31] With such diagnostic uncertainty, imaging, eg, computed tomography (CT) scan, can help distinguish between mild to moderate elevation of enzymes due to DKA and acute pancreatitis. Lipid derangement is also commonly seen in patients with DKA. In one study, before insulin treatment, the mean plasma triglyceride and cholesterol levels were 574 mg/dL (range, 53-2355 mg/dL) and 212 mg/dL (range, 118-416 mg/dL), respectively. Insulin therapy resulted in a rapid decrease in plasma triglyceride levels to below 150 mg/dL at 24 hours. Plasma apolipoprotein (apo) B levels were in the normal upper range (101 mg/dL) before treatment. These levels decreased with therapy due to significant decreases in VLDL, but not in IDL or LDL apoB.[32] Additional Diagnostic Studies

Lipid derangement is also commonly seen in patients with DKA. In one study, before insulin treatment, the mean plasma triglyceride and cholesterol levels were 574 mg/dL (range, 53-2355 mg/dL) and 212 mg/dL (range, 118-416 mg/dL), respectively. Insulin therapy resulted in a rapid decrease in plasma triglyceride levels to below 150 mg/dL at 24 hours. Plasma apolipoprotein (apo) B levels were in the normal upper range (101 mg/dL) before treatment. These levels decreased with therapy due to significant decreases in VLDL, but not in IDL or LDL apoB.[32] Additional Diagnostic Studies An electrocardiogram (ECG) will help detect ischemic changes or signs of hypokalemia or hyperkalemia. Peaked T waves can signal hyperkalemia, and low T waves with a U wave indicate hypokalemia. A chest x-ray may be performed to rule out consolidation. While magnetic resonance imaging (MRI) is more sensitive, CT imaging of the brain can also detect significant cerebral edema and is typically more readily available. However, diagnostic imaging should not delay treatment if cerebral edema is suspected.

Adult Diabetic Ketoacidosis Management The primary management approach to DKA management includes fluid resuscitation and maintenance, insulin therapy, electrolyte replacement, and supportive care.[33] Fluid Resuscitation In patients with DKA, the fluid deficit could be up to 10% to 15% of the body weight.[2] Therefore, immediate fluid resuscitation is vital to correct hypovolemia, restore tissue perfusion, and clear ketones. Hydration subsequently improves glycemic control independent of insulin. Choice of fluids Isotonic fluids have been well established for over 50 years as the preferred fluids. A 2013 meta-analysis compared colloids and crystalloids in critically ill patients, and crystalloids were not found to be inferior to colloids.[34] Traditionally, 0.9% normal saline has been used. Some concern has been raised that normal saline may contribute to hyperchloremia and hyperchloremic metabolic acidosis; however, this typically occurs when normal saline is used in large volumes. Small studies comparing normal saline with crystalloid solutions, such as Ringer's lactate, have been conducted. These studies did not show differences in clinical outcomes.[35][36][37] Normal saline remains the standard for initial hydration. Infusion rate An initial infusion of 15 to 20 mL/kg in the first hour is typically appropriate. Aggressive hydration at 1 L/hour for 4 hours was compared in a study to a slower rate of hydration at half the rate. Slower hydration was found to be equally effective.[38] However, in critically ill patients, including those with hypotension, aggressive fluid therapy is preferred. The risk of cerebral edema in patients with aggressive early volume resuscitation has been extensively debated. Some studies have demonstrated rates of increased cerebral edema with aggressive volume, particularly in the pediatric population. Yet other studies show no difference in outcome and theorize that patients at the most significant risk from cerebral edema present at a later stage and are the most severely volume-depleted.[39]

An initial infusion of 15 to 20 mL/kg in the first hour is typically appropriate. Aggressive hydration at 1 L/hour for 4 hours was compared in a study to a slower rate of hydration at half the rate. Slower hydration was found to be equally effective.[38] However, in critically ill patients, including those with hypotension, aggressive fluid therapy is preferred. The risk of cerebral edema in patients with aggressive early volume resuscitation has been extensively debated. Some studies have demonstrated rates of increased cerebral edema with aggressive volume, particularly in the pediatric population. Yet other studies show no difference in outcome and theorize that patients at the most significant risk from cerebral edema present at a later stage and are the most severely volume-depleted.[39] The subsequent choice for fluid maintenance replacement depends on hemodynamics, hydration status, serum electrolyte levels, and urinary output.[2] In patients with high serum sodium levels, 0.45% NaCl infused at 4 to 14 mL/kg/hour or 250 to 500 mL/hour is appropriate. For patients with hyponatremia, 0.9% sodium chloride (NaCl) is preferred at a similar rate.[40] Maintenance fluids may need to be adjusted if hyperchloremic metabolic acidosis becomes a concern; in this case, the fluid may be switched to a Ringer's lactate solution. Insulin Therapy The discovery of insulin, along with the antibiotics, has led to a drastic decrease in mortality with DKA, down to 1%. Intravenous insulin by continuous infusion is the standard of care. Insulin therapy should only be initiated when the serum potassium level is 3.5 mmol/L or higher. If serum potassium is below this limit, initiating insulin will worsen hypokalemia by shifting potassium into the intracellular space. This reduction in potassium can result in cardiac arrhythmias, cardiac arrest, and respiratory arrest due to respiratory muscle weakness.

The discovery of insulin, along with the antibiotics, has led to a drastic decrease in mortality with DKA, down to 1%. Intravenous insulin by continuous infusion is the standard of care. Insulin therapy should only be initiated when the serum potassium level is 3.5 mmol/L or higher. If serum potassium is below this limit, initiating insulin will worsen hypokalemia by shifting potassium into the intracellular space. This reduction in potassium can result in cardiac arrhythmias, cardiac arrest, and respiratory arrest due to respiratory muscle weakness. Treatment protocols have recommended administering an initial bolus of 0.1 U/kg, followed by an infusion of 0.1 U/kg/h. A more recent prospective randomized trial demonstrated that a bolus is not necessary if patients are given an hourly insulin infusion at 0.14 U/kg/hr.[41] When the plasma glucose level reaches 200 to 250 mg/dL, and if the patient still has an anion gap, dextrose-containing fluids should be initiated. The insulin infusion rate may need to be reduced to 0.05 U/kg/hr. In a patient with euglycemic DKA (glucose level <250 mg/dL), insulin boluses should not be administered to prevent a rapid decline in blood glucose levels. The insulin infusion is given at a lower rate of 0.05 U/kg/hr. These patients should receive dextrose 5% to 10% in the fluids from the beginning. Adult patients with uncomplicated, mild DKA can be treated with subcutaneous insulin lispro administered hourly in a nonintensive care setting. This approach may be a safe and cost-effective alternative to intravenous regular insulin in the intensive care setting, as demonstrated in numerous studies.[42] Patients should receive subcutaneous insulin lispro with an initial dose of 0.1 U/kg, followed by 0.1 U/kg every hour until their blood glucose level is less than 250 mg/dL. The insulin dose is then given at 0.1 U/kg every hour or 0.2 U/kg every 2 hours, until the resolution of DKA.[42] Similarly, insulin aspart has been used and found to be equally efficacious.[43] Patients with DKA should be treated with insulin until the condition resolves. Criteria indicating the resolution of DKA include a blood glucose level of less than 200 mg/dL and 2 of the following: A serum bicarbonate level of ≥15 mEq/L Venous pH of >7.3 A calculated anion gap of ≤12 mEq/L

Adult patients with uncomplicated, mild DKA can be treated with subcutaneous insulin lispro administered hourly in a nonintensive care setting. This approach may be a safe and cost-effective alternative to intravenous regular insulin in the intensive care setting, as demonstrated in numerous studies.[42] Patients should receive subcutaneous insulin lispro with an initial dose of 0.1 U/kg, followed by 0.1 U/kg every hour until their blood glucose level is less than 250 mg/dL. The insulin dose is then given at 0.1 U/kg every hour or 0.2 U/kg every 2 hours, until the resolution of DKA.[42] Similarly, insulin aspart has been used and found to be equally efficacious.[43] Patients with DKA should be treated with insulin until the condition resolves. Criteria indicating the resolution of DKA include a blood glucose level of less than 200 mg/dL and 2 of the following: A serum bicarbonate level of ≥15 mEq/L Venous pH of >7.3 A calculated anion gap of ≤12 mEq/L Patients can be transitioned to subcutaneous insulin administration when DKA has resolved and they are able to eat. Those previously treated with insulin may be recommended to adjust their home dose if they have been well controlled. Insulin-naive patients should receive a multidose insulin regimen beginning at a dose of 0.5 to 0.8 U/kg/day. To prevent the recurrence of ketoacidosis during the transition period, insulin infusion should be continued for 2 hours after the start of subcutaneous insulin. Blood sugar and a complete metabolic profile should be rechecked before stopping the insulin drip. If the patient cannot tolerate oral intake, intravenous insulin and fluids may be continued. The use of long-acting insulin analogs during the initial management of DKA may facilitate the transition from intravenous to subcutaneous insulin therapy.[44] Electrolyte Replacement Potassium

Insulin-naive patients should receive a multidose insulin regimen beginning at a dose of 0.5 to 0.8 U/kg/day. To prevent the recurrence of ketoacidosis during the transition period, insulin infusion should be continued for 2 hours after the start of subcutaneous insulin. Blood sugar and a complete metabolic profile should be rechecked before stopping the insulin drip. If the patient cannot tolerate oral intake, intravenous insulin and fluids may be continued. The use of long-acting insulin analogs during the initial management of DKA may facilitate the transition from intravenous to subcutaneous insulin therapy.[44] Electrolyte Replacement Potassium Patients with DKA are often found to initially have mild to moderate hyperkalemia, despite a total body deficit of potassium. The initiation of insulin causes an intracellular shift of potassium, lowering the potassium concentration and potentially resulting in severe hypokalemia.[45][46] Hence, patients with serum potassium levels below 3.5 mmol/L require initial management with fluid resuscitation and potassium replacement. It is advisable to delay the commencement of insulin until potassium levels exceed 3.5 mmol/L to prevent cardiac arrhythmias, arrest, and respiratory muscle weakness.[44] In other patients, potassium replacement should be initiated when the serum concentration is below 5.2 mEq/L to maintain a level between 4 and 5 mEq/L. Administering 20 to 30 mEq of potassium per liter of fluids is sufficient for most patients; however, lower doses are required for patients with acute or chronic renal failure.[47] Magnesium Hypokalemia is commonly associated with hypomagnesemia. Repletion of both potassium and magnesium may be necessary, and improving potassium levels can be challenging until magnesium levels are replenished. Bicarbonate

Patients with DKA are often found to initially have mild to moderate hyperkalemia, despite a total body deficit of potassium. The initiation of insulin causes an intracellular shift of potassium, lowering the potassium concentration and potentially resulting in severe hypokalemia.[45][46] Hence, patients with serum potassium levels below 3.5 mmol/L require initial management with fluid resuscitation and potassium replacement. It is advisable to delay the commencement of insulin until potassium levels exceed 3.5 mmol/L to prevent cardiac arrhythmias, arrest, and respiratory muscle weakness.[44] In other patients, potassium replacement should be initiated when the serum concentration is below 5.2 mEq/L to maintain a level between 4 and 5 mEq/L. Administering 20 to 30 mEq of potassium per liter of fluids is sufficient for most patients; however, lower doses are required for patients with acute or chronic renal failure.[47] Magnesium Hypokalemia is commonly associated with hypomagnesemia. Repletion of both potassium and magnesium may be necessary, and improving potassium levels can be challenging until magnesium levels are replenished. Bicarbonate Bicarbonate replacement does not appear to be beneficial, as a study demonstrated the difference in time to resolution of acidosis (8 hours versus 8 hours; P = 0.7) and time to hospital discharge (68 hours versus 61 hours, P = 0.3) was found to be statistically insignificant between patients who received intravenous bicarbonate (n = 44) compared with those who did not (n = 42).[48] In another pediatric study, children with DKA who had low PaCO2 and high BUN concentrations at presentation and those treated with bicarbonate were at increased risk for cerebral edema.[49] Proposed pitfalls of the use of sodium bicarbonate therapy in DKA may include paradoxical CSF acidosis, hypokalemia, a large sodium bolus, and cerebral edema. However, this therapy may be used in patients with severe acidemia. The most recent ADA guidelines recommend the use of sodium bicarbonate therapy in patients with a pH level below 7.1.[48] Phosphate

Bicarbonate replacement does not appear to be beneficial, as a study demonstrated the difference in time to resolution of acidosis (8 hours versus 8 hours; P = 0.7) and time to hospital discharge (68 hours versus 61 hours, P = 0.3) was found to be statistically insignificant between patients who received intravenous bicarbonate (n = 44) compared with those who did not (n = 42).[48] In another pediatric study, children with DKA who had low PaCO2 and high BUN concentrations at presentation and those treated with bicarbonate were at increased risk for cerebral edema.[49] Proposed pitfalls of the use of sodium bicarbonate therapy in DKA may include paradoxical CSF acidosis, hypokalemia, a large sodium bolus, and cerebral edema. However, this therapy may be used in patients with severe acidemia. The most recent ADA guidelines recommend the use of sodium bicarbonate therapy in patients with a pH level below 7.1.[48] Phosphate The role of phosphate replacement in DKA has been looked at in different studies. In a randomized study involving 44 patients, phosphate therapy did not alter the duration of DKA, the insulin dosage required to correct acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the treatment for DKA in most patients. An unusual case of severe hypophosphatemia (1.0 mg/dl) related seizure in a child with DKA has been described in the literature.[50][51][50] Laboratory Monitoring Hourly point-of-care glucose testing provides essential information for guiding therapy and monitoring response to treatment. Frequent assessment of glucose trends allows clinicians to adjust insulin dosing and fluid management promptly. Serum glucose and electrolyte levels should be measured every 2 hours until the patient demonstrates clinical stability, after which testing may be reduced to every 4 hours. Initial evaluation must also include blood urea nitrogen (BUN) to assess renal function and guide fluid replacement strategies. Venous blood gas (VBG) or arterial blood gas (ABG) testing should be obtained at presentation, with repeat testing as indicated by clinical status or precipitating events. Supportive Therapy Intubation

Serum glucose and electrolyte levels should be measured every 2 hours until the patient demonstrates clinical stability, after which testing may be reduced to every 4 hours. Initial evaluation must also include blood urea nitrogen (BUN) to assess renal function and guide fluid replacement strategies. Venous blood gas (VBG) or arterial blood gas (ABG) testing should be obtained at presentation, with repeat testing as indicated by clinical status or precipitating events. Supportive Therapy Intubation Multiple risks accompany intubation in patients with DKA, making avoidance the preferred strategy whenever possible. Adherence to recommended management with fluids and insulin typically leads to the resolution of acidosis and clinical improvement, often without the need for airway intervention. Patients typically attempt to compensate for severe acidosis by generating a respiratory alkalosis, which manifests as tachypnea and Kussmaul breathing. Intubation becomes necessary when patients lose the ability to maintain this compensatory response, often due to coma or profound fatigue. However, intubation in DKA carries considerable risk, including elevations in PaCO2 during sedation or paralysis that further lower the pH, an increased likelihood of aspiration due to gastroparesis, and difficulty replicating the degree of respiratory compensation once mechanical ventilation begins. When intubation cannot be avoided, ventilator settings must closely match the patient’s minute ventilation to maintain respiratory alkalosis and counteract metabolic acidosis. Failure to achieve this balance can worsen acidosis and result in cardiac arrest. An initial tidal volume of 8 mL/kg based on ideal body weight, along with a respiratory rate approximating the patient’s compensatory rate, provides a reasonable starting point. Vigilance remains necessary to prevent auto-PEEP, particularly in patients with rapid respiratory rates.[52] Cerebral edema treatment Monitoring mental status and performing thorough neurologic examinations remain essential for all patients with DKA. Clinicians should maintain a very low threshold for treating cerebral edema in patients who present as severely obtunded, comatose, or who demonstrate declining mental status or focal neurologic deficits despite appropriate DKA management.

Monitoring mental status and performing thorough neurologic examinations remain essential for all patients with DKA. Clinicians should maintain a very low threshold for treating cerebral edema in patients who present as severely obtunded, comatose, or who demonstrate declining mental status or focal neurologic deficits despite appropriate DKA management. Treatment options to reduce elevated intracranial pressure include mannitol and hypertonic saline. Both agents increase serum osmolarity, drawing water out of brain tissue and thereby decreasing brain volume. Hypertonic saline offers the advantage of a lower risk of hypotension and may provide additional benefits, including improved cerebral blood flow and enhanced oxygenation. The choice between agents depends on availability and patient-specific considerations.[53] Precipitating events Infection represents a common precipitating factor for DKA in both patients with new-onset and previously diagnosed diabetes. When clinical suspicion for infection arises, prompt initiation of appropriate antibiotic therapy is essential to address the underlying cause and prevent further metabolic deterioration. Additional events, eg, medication changes, acute illness, or substance use, can also trigger DKA. Effective management requires simultaneous treatment of the metabolic derangements associated with DKA and any underlying etiologies. Addressing both aspects ensures stabilization of the patient’s condition and reduces the risk of recurrence or complications.

DKA has a diverse presentation, and this is why several other common pathologies may mimic this diagnosis. The following differential diagnoses should be considered in patients presenting with clinical features of DKA: Hyperosmolar hyperglycemic nonketotic syndrome Starvation ketosis Myocardial infarction Pancreatitis Alcoholic ketoacidosis Lactic acidosis Sepsis Toxicologic exposure (eg, ethylene glycol, methanol, paraldehyde, and salicylate) Diabetic medication overdose Uremia

DKA still carries a mortality rate of 0.2 to 2.5% in developing countries. Patients who present in a comatose state, hypothermia, and oliguria tend to have the worst outcomes. For most patients treated promptly, the outcomes are good, especially if the trigger is not an infection. Older adult patients with concurrent illnesses, eg, myocardial infarction, pneumonia, or sepsis, tend to have extended hospital stays and high mortality. The most important cause of mortality is cerebral edema, usually seen in younger patients. Cerebral edema is primarily due to intracellular shifts. Another important cause of morbidity is renal dysfunction. A recent study has noted that among patients with type 2 diabetes who develop DKA, a high risk of stroke within the first 6 months after the event is present.

Hypoglycemia represents the most common complication during the treatment of DKA, affecting an estimated 5% to 25% of patients.[47] Acute consequences of hypoglycemia include seizures, cardiac arrhythmias, and other cardiovascular events.[54] Hourly blood glucose monitoring during the acute treatment phase remains essential for preventing and promptly addressing these complications. Hypokalemia frequently occurs in DKA, necessitating close monitoring and timely intervention. Severe hypokalemia can lead to muscle weakness, cardiac arrhythmias, and cardiac arrest.[14] Other electrolyte disturbances, eg, hyperchloremia, hypomagnesemia, and hyponatremia, may also develop, with hyperchloremia affecting up to a third of patients.[55] Cerebral edema, although less common in adults than in children, poses a serious risk. Contributing factors include younger age, new-onset diabetes, prolonged symptom duration, severe acidosis, low initial bicarbonate or sodium levels, elevated glucose at presentation, rapid fluid resuscitation, and retained gastric fluid.[49] Rhabdomyolysis may occur in patients with DKA, particularly in cases of severe hypophosphatemia, and can result in acute kidney injury.[56] Acute respiratory failure may develop secondary to pneumonia, acute respiratory distress syndrome (ARDS), or pulmonary edema. Two recognized forms of pulmonary edema in DKA include those caused by elevated pulmonary venous pressure and increased pulmonary capillary permeability.[57] Rare complications such as thrombotic thrombocytopenic purpura (TTP) and myocarditis have also been reported in association with DKA.

Deterrence of DKA relies on early recognition of risk factors, adherence to therapy, and effective management of underlying conditions. Patients benefit from education that emphasizes the importance of consistent blood glucose monitoring, proper insulin administration, and prompt medical evaluation for infections or other acute illnesses. Guidance on medication safety, including awareness of agents, eg, SGLT-2 inhibitors or corticosteroids that may increase the risk of DKA, also plays a critical role in prevention. Clinicians should reinforce the need for individualized sick-day management plans to help patients adjust insulin doses and maintain hydration during periods of stress or illness. Patient education should also address recognition of early warning signs, including polyuria, polydipsia, fatigue, nausea, abdominal pain, or changes in mental status. Teaching patients how to check for ketones at home during episodes of illness or uncontrolled hyperglycemia provides another safeguard. Strong communication between healthcare practitioners and patients fosters better adherence, reduces preventable short and long-term complications, and supports long-term glycemic control. Ongoing education, reinforced during routine visits, empowers patients and caregivers to respond quickly to changes in clinical status, thereby decreasing the risk of DKA recurrence and improving overall outcomes.

DKA represents a life-threatening complication of diabetes characterized by hyperglycemia, acidosis, and ketonemia. While most commonly associated with type 1 diabetes, DKA can also develop in patients with type 2 diabetes. Triggers include infection, new-onset diabetes, nonadherence to treatment, certain medications, and acute medical stressors. Early recognition, timely intervention, and patient education remain central to preventing complications and reducing recurrence. Effective management of DKA requires interprofessional collaboration and clearly defined responsibilities across the healthcare team. Physicians, general practitioners, and advanced practitioners must rapidly diagnose, initiate fluid and insulin therapy, and address underlying causes. Nurses play a critical role in monitoring vital signs, neurologic status, and laboratory parameters, ensuring timely interventions. Pharmacists optimize insulin regimens, evaluate potential drug interactions, and educate patients on the safety of their medications. Coordinated communication among all team members enhances patient-centered care by aligning treatment goals, ensuring patient safety, and supporting adherence strategies that reduce morbidity and improve long-term outcomes.